Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines

Carcinogenesis

Volumn 27, Issue 2, 2006, Pages 197-204

  Drucker, Liat ^a   Tohami, Tali ^a,b   Tartakover Matalon, Shelly ^a   Zismanov, Victoria ^a,b   Shapiro, Hava ^a   Radnay, Judith ^a   Lishner, Michael ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD19 ANTIGEN; CD81 ANTIGEN; CD82 ANTIGEN; CD9 ANTIGEN; MESSENGER RNA; RESTRICTION ENDONUCLEASE; TETRASPANIN; TRICHOSTATIN A;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CANCER GROWTH; CELL INTERACTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MICROENVIRONMENT; MULTIPLE MYELOMA; MYELOMA CELL; POLYMERASE CHAIN REACTION; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION;

ANTIGENS, CD; CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; DOWN-REGULATION; GENE SILENCING; HUMANS; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS);

EID: 31544459798     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi209     Document Type: Article

References (41)

1. Laird,P.W. (2003) The power and promise of DNA methylation markers. Nat. Rev., 3, 253-266.
2. Turker,M. (2002) Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene, 21, 5388-5393.
3. Karpf,A.R. and Jones,D.A. (2002) Reactivating the expression of methylation silenced genes in human cancer. Oncogene, 21, 5496-5503.
4. Bird,A. (2002) DNA methylation patterns and epigenetic memory. Genes Dev., 16, 6-21.
5. Ehrlich,M. (2002) DNA methylation in cancer: Too much, but also too little. Oncogene, 21, 5400-5413.
6. Ng,M.H., Wong,I.H. and Lo,K.W. (1999) DNA methylation changes and multiple myeloma. Leuk. Lymphoma, 34, 463-472.
7. INK4A gene in multiple myeloma. Br. J. Haematol., 10, 558-564.
8. Mateos,M.V., Gracia-Sanz,R., Lopez-Perez,R. et al. (2002) Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br. J. Haematol., 118, 1034-1040.
9. Ng,M.H.L., To,K.W., Lo,K.W., Chan,S., Tsang,K.S., Cheng,S.H. and Ng,H.K. (2001) Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin. Cancer Res., 7, 1724-1729.
10. Ng,M.H.L. (2002) Death associated protein kinase: From regulation of apoptosis to tumor suppressive functions and B cell malignancies. Apoptosis, 7, 261-270.
11. Pompeia,C., Hodge,D.R., Plass,C., Wu,Y.Z., Marquez,V.E., Kelley,J.A. and Farrar,W.L. (2004) Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res., 64, 3465-3473.
12. Galm,O., Yoshikawa,H., Esteller,M., Osieka,R. and Herman,J.G. (2003) SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood, 101, 2784-2788.
13. Malone,C.S., Miner,M.D., Doerr,J.R., Jackson,J.P., Jacobson,S.E., Wall,R. and Teitell,M. (2001) CmC(A/T)GG DNA methylation in mature B cell lymphoma gene silencing. Proc. Natl Acad. Sci. USA, 98, 10404-10409.
14. Chim,C.S., Kwong,Y.L., Fung,T.K. and Liang,R. (2004) Methylation profiling in multiple myeloma. Leuk. Res., 28, 379-385.
15. Du,H.L., Shi,Y.J., Bu,D.F. and Wu,S.L. (2002) Apoptosis and re-expression of p-16 in the myeloma cell line U266 induced by synergy of histone deacetylase inhibitor and demethylating agent. Ai Zheng, 21, 1057-1061.
16. Mitsiades,N., Mitsiades,C.S., Richardson,P.G. et al. (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood, 101, 4055-4062.
17. Catley,L., Weisberg,E., Tai,Y.T. et al. (2003) NVP-LaQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood, 102, 2615-2622.
18. Teoh,G. and Anderson,K.C. (1997) Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol. Oncol. Clin. North Am., 11, 27-42.
19. Epstein,J. and Yaccoby,S. (2002) Interactions between the bone marrow stroma and myeloma. Hematol. J., 4, 310-314.
20. Tomlinson,M.G. and Wright,M.D. (1996) A new transmembrane 4-superfamily molecule in the nematode, Caenorhabditis elegans. J. Mol. Evol., 43, 312-314.
21. Maecker,H.T., Todd,S.C. and Levy,S. (1996) The tetraspanin superfamily: molecular facilitators. FASEB J., 11, 428-442.
22. Tole,S. and Patterson,P.H. (1993) Distribution of CD9 in the developing and mature rat nervous system. Dev. Dyn., 197, 94-106.
23. Kopczynski,C.C., Davis,G.W. and Goodman,C.S. (1996) A neural tetraspanin, encoded by late bloomer that facilitates synapse formation. Science, 271, 1867-1870.
24. Anton,E.S., Hadjiargyrou,M., Patterson,P.H. and Mathew,W.D. (1995) CD9 plays a role in schwann cell migration in vitro. J. Neurosci., 15, 584-595.
25. Levy,S., Todd,S.C. and Maecker,H.T. (1998) CD81 (TAPA-1): A molecule involved in signal transduction and cell adhesion in the immune system. Annu. Rev. Immunol., 16, 89-109.
26. Koyama,Y., Suzuki,M. and Yoshida,T. (1998) CD63, a member of tetraspan transmembrane protein family, induces cellular spreading by reaction with monoclonal antibody on substrata. Biochem. Biophys. Res. Commun., 246, 841-846.
27. Beinert,T., Munzing,S., Possinger,K. and Krombach,F. (2000) Increased expression of the tetraspanins CD53 and CD63 on apoptotic human neutrophils. J. Leukocyte Biol., 67, 369-373.
28. Boucheix,C., Duc,G.H.T., Jasmin,C. and Rubinstein,E. (2001) Tetraspanins and malignancy. Exp. Rev. Mol. Med., 2001, 1-17.
29. Uzawa,K., Ono,K., Suzuki,H., Tanak,C., Yakushiji,T., Yamamoto,N., Yokoe,H. and Tanzawa,H. (2002) High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis. Clin. Cancer Res., 8, 828-835.
30. Wang,X.Q., Alfaro,M.L., Evans,G.F. and Zuckerman,S.H. (2002) Histone deacetylase inhibition results in decreased macrophage CD9 expression. Biochem. Biophys. Res. Commun., 294, 660-666.
31. Tohami,T., Drucker,L., Radnay,J., Shapira,H. and Lishner,M. (2004) Expression of Tetraspanins in peripheral blood leukocytes: A comparison between normal and infectious conditions. Tissue Antigens, 64, 235-242.
32. Gardiner-Garden,M. and Frommer,M. (1987) CpG islands in vertebrate genomes. J. Mol. Biol., 196, 261-282.
33. Borson,D., Lacy,M.Q. and Wettstein,P.J. (2001) Altered mRNA expression of pax5 and Blimp-1 in B cells in multiple myeloma. Blood, 100, 4629-4639.
34. Danbara,M., Kameyama,K., Higashihara,M. and Takagaki,Y. (2001) DNA methylation dominates transcriptional silencing of Pax5 in terminally differentiated b cell lines. Mol. Immunol., 38, 1161-1166.
35. Chim,C.S., Liang,R. and Kwong,Y.L. (2002). Hypermethylation of gene promoters in hematological neoplasia. Hematol. Oncol., 20, 167-176.
36. Harikrishnan,K.N., Chow,M.Z., Baker,E.K. et al. (2005) Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat. Genet., 37, 254-264.
37. Odintsova,E., Voortman,J., Gilbert,E. and Berditchevski,F. (2003) Tetraspanin CD82 regulates compartmentalization and ligand-induced dimerization of EGFR. J. Cell Sci., 116 (pt 22), 4557-4566.
38. Kaji,K. and Kudo,A. (2004) The mechanism of sperm-oocyte fusion in mammals. Reproduction, 127, 423-429.
39. Tanio,Y., Yamazaki,H., Kunisada,T., Miyake,K. and Hayashi,S.I. (1999) CD9 molecule expressed on stromal cells is involved in osteoclastogenesis. Exp. Hematol., 27, 853-859.
40. Damnio,J.S., Cress,A.E., Hazlehurst,L.A., Shtil,A.A. and Dalton,W.S. (1999) Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93, 1658-1667.
41. Nefedova,Y., Landowski,T.H. and Dalton,W.S. (2003) Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia, 17, 1175-1182.